NCT04293276
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with symptomatic brain metastasis; Patients who have not received at least 1 line treatment in the past; Patients with a history of HER2 targeting tyrosine kinase inhibitors (e.g. Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib)
https://ClinicalTrials.gov/show/NCT04293276